DSIP in Australia: Delta Sleep-Inducing Peptide Research Guide & Where to Buy

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (nine amino acids) first isolated from rabbit cerebral venous blood in 1977 by Monnier and colleagues in Switzerland. It was originally characterised by its ability to induce delta-wave (slow-wave) sleep when administered to rabbits, giving rise to its name.

DSIP is endogenously produced and has been detected in the hypothalamus, limbic system, pituitary gland, and peripheral organs including the gut and pancreas. Its biological activity spans the central nervous system and periphery, and it is thought to modulate multiple physiological systems beyond sleep alone.

DSIP has been investigated across several research domains since its discovery:

Sleep architecture: Early animal studies demonstrated that DSIP administration increased slow-wave (delta) sleep and reduced wakefulness and REM sleep in rabbits and rats. Human studies conducted in the 1980s and 1990s reported mixed results, some showing increased slow-wave sleep and improved sleep quality, others showing minimal effects, with variability attributed to differences in dosing, route of administration, and individual factors. The human evidence base remains limited by modern standards.

Stress and neuroendocrine modulation: DSIP has been shown in preclinical models to modulate the hypothalamic-pituitary-adrenal (HPA) axis, attenuating stress-induced ACTH and cortisol release in some studies. It has also been reported to influence the release of growth hormone, LH, and other pituitary hormones, though the regulatory mechanisms are not fully elucidated.

Antioxidant and neuroprotective effects: More recent preclinical research has explored DSIP's potential antioxidant properties and protective effects against oxidative stress in neuronal models.

Pain and withdrawal: Some clinical research from Eastern European institutions in the 1990s investigated DSIP in the context of chronic pain and opiate withdrawal, reporting reductions in withdrawal symptoms, though methodology in some of these studies has been questioned.

Research-grade DSIP is supplied as a lyophilised powder in sealed vials. OzPeps stocks DSIP in 10mg vials, which is the standard research format. Once reconstituted with bacteriostatic water, DSIP solution should be stored at 2–8°C.

DSIP is a relatively small, stable peptide in lyophilised form; stored at −20°C, lyophilised DSIP maintains integrity for 24+ months. Reconstituted solutions are typically stable for up to 28 days when refrigerated.

View DSIP 10mg stock and pricing →

DSIP lyophilised powder is reconstituted with bacteriostatic water prior to use in research. Reconstitute and store research-grade vials following the standard protocol, see our peptide reconstitution & storage guide. Compound-specific note: DSIP dissolves readily due to its small size.

Use OzPeps' free reconstitution calculator to confirm volumes and per-unit concentrations.

Sleep peptide research is an active area with significant interest in compounds that modulate sleep architecture without the dependency profiles associated with conventional pharmacological sleep aids. DSIP's endogenous origin and multi-system effects make it an interesting research subject, particularly for researchers studying:

• HPA axis regulation and stress response
• Slow-wave sleep induction and sleep quality
• Neuroendocrine interactions between sleep and hormone release
• Neuroprotection and antioxidant mechanisms in the CNS

For researchers studying sleep-related peptides more broadly, DSIP is often considered alongside Epithalon (which has also been studied for circadian rhythm effects) and Selank (for anxiety and stress modulation). See the Selank research guide and Epithalan research guide for related compounds.

OzPeps supplies research-grade DSIP 10mg Australia-wide with fast dispatch, discreet packaging, and crypto payment options. View DSIP stock and pricing →

DSIP is sold by OzPeps strictly for laboratory and in-vitro research purposes. It is not a TGA-approved therapeutic good, is not intended for human or animal consumption, and is not sold for the treatment or prevention of any medical condition. The sleep and neuroendocrine research cited in this article is derived primarily from preclinical animal models and early human studies; evidence quality varies. Researchers are responsible for compliance with all applicable regulations.